Context Therapeutics (CNTX) Stock Analysis

What Context Therapeutics does

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Key metrics

ETFs linked to CNTX

Broad-market and Healthcare sector ETFs an investor holding Context Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CNTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Context Therapeutics?

Context Therapeutics trades under the ticker CNTX on NASDAQ.

Which exchange is CNTX listed on?

CNTX is listed on NASDAQ.

What sector does Context Therapeutics operate in?

Context Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CNTX in a portfolio?

PortView shows CNTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.